Jade Ghosn

20.4k total citations · 3 hit papers
177 papers, 4.7k citations indexed

About

Jade Ghosn is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jade Ghosn has authored 177 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Infectious Diseases, 100 papers in Virology and 59 papers in Epidemiology. Recurrent topics in Jade Ghosn's work include HIV Research and Treatment (89 papers), HIV/AIDS Research and Interventions (87 papers) and HIV/AIDS drug development and treatment (85 papers). Jade Ghosn is often cited by papers focused on HIV Research and Treatment (89 papers), HIV/AIDS Research and Interventions (87 papers) and HIV/AIDS drug development and treatment (85 papers). Jade Ghosn collaborates with scholars based in France, United States and United Kingdom. Jade Ghosn's co-authors include Christine Katlama, Nathan Peiffer‐Smadja, Yousra Kherabi, Thibault Fiolet, Marie‐Laure Chaix, Christine Rouzioux, Dominique Costagliola, Stéphanie Dominguez, Claudine Duvivier and Constance Delaugerre and has published in prestigious journals such as The Lancet, Nature Medicine and Nature Communications.

In The Last Decade

Jade Ghosn

166 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

2021 609 citations Jade Ghosn et al. profile →
HIV

2018 215 citations Jade Ghosn, Christine Katlama et al. profile →
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

2024 69 citations Jean‐Michel Molina, Béatrice Berçot et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jade Ghosn France	34	3.1k	1.9k	1.2k	666	446	177	4.7k
Andrea Gori Italy	40	3.2k 1.0×	1.5k 0.8×	2.2k 1.9×	898 1.3×	202 0.5×	300	5.8k
Praphan Phanuphak Thailand	45	4.7k 1.5×	2.8k 1.5×	2.8k 2.3×	898 1.3×	373 0.8×	276	7.4k
Hans‐Jürgen Stellbrink Germany	30	2.3k 0.7×	1.9k 1.0×	1.0k 0.8×	945 1.4×	295 0.7×	74	3.7k
Dominique Salmon‐Céron France	35	2.0k 0.7×	931 0.5×	2.2k 1.8×	676 1.0×	1.1k 2.6×	161	4.8k
John S. Lambert Ireland	38	2.4k 0.8×	1.5k 0.8×	1.7k 1.4×	930 1.4×	616 1.4×	215	4.8k
Dominique Salmon France	35	1.8k 0.6×	779 0.4×	2.0k 1.7×	579 0.9×	645 1.4×	147	4.7k
Brian K. Agan United States	36	2.2k 0.7×	1.7k 0.9×	1.6k 1.3×	1.1k 1.6×	484 1.1×	167	4.6k
Jonathan B. Angel Canada	41	1.9k 0.6×	1.7k 0.9×	1.4k 1.1×	547 0.8×	316 0.7×	177	5.5k
Loredana Sarmati Italy	29	1.7k 0.5×	947 0.5×	1.2k 1.0×	189 0.3×	335 0.8×	185	3.1k
Pragna Patel United States	37	2.3k 0.8×	991 0.5×	2.0k 1.7×	959 1.4×	87 0.2×	111	5.2k

Countries citing papers authored by Jade Ghosn

Since Specialization

Citations

This map shows the geographic impact of Jade Ghosn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jade Ghosn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jade Ghosn more than expected).

Fields of papers citing papers by Jade Ghosn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jade Ghosn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jade Ghosn. The network helps show where Jade Ghosn may publish in the future.

Co-authorship network of co-authors of Jade Ghosn

This figure shows the co-authorship network connecting the top 25 collaborators of Jade Ghosn. A scholar is included among the top collaborators of Jade Ghosn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jade Ghosn. Jade Ghosn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghosn, Jade, Jeremy Chow, Miguel Górgolas, et al.. (2025). Rapid start with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment in people with human immunodeficiency virus‐1 (HIV‐1): A systematic literature review of clinical and patient‐reported outcomes. HIV Medicine. 26(9). 1375–1394.

Rockstroh, Jürgen K., Roger Paredes, Pedro Cahn, et al.. (2025). Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clinical Infectious Diseases. 81(2). 322–332.

Brunet‐Possenti, F., Jean‐Luc Prétet, Lydia Deschamps, et al.. (2025). Detection of alpha-human papillomavirus types in cutaneous squamous cell carcinoma associated with markers of carcinogenesis: a retrospective study. Clinical and Experimental Dermatology. 50(11). 2147–2152.

Geretti, Anna María, Marta Boffito, Stefano Bonora, et al.. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 12(7). ofaf368–ofaf368. 2 indexed citations

Berçot, Béatrice, Lambert Assoumou, François Caméléna, et al.. (2025). Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial. Clinical Infectious Diseases.

Gac, Sylvie Le, et al.. (2024). Proof of concept of a sexual health outreach program led by community health workers in homeless hostels in the greater Paris region. Frontiers in Public Health. 11. 1305874–1305874. 3 indexed citations

Siguier, Martin, Olivier Robineau, M. Valette, et al.. (2024). Incidence and factors associated with PrEP discontinuation in France. Journal of Antimicrobial Chemotherapy. 79(7). 1555–1563. 2 indexed citations

Bertine, Mélanie, Gilles Peytavin, Antoine Bachelard, et al.. (2024). Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing Regimen. Clinical Infectious Diseases. 81(2). 341–344. 2 indexed citations

Ghosn, Jade, Lambert Assoumou, Emma Rubenstein, et al.. (2024). Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial. The Lancet Regional Health - Europe. 45. 101020–101020. 2 indexed citations

10.

Serris, Alexandra, Valentine Marie Ferré, Quentin Le Hingrat, et al.. (2024). Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results. Journal of Antimicrobial Chemotherapy. 79(11). 2932–2938. 6 indexed citations

11.

Kiem, Cécile Tran, Valérie Olié, Juliette Paireau, et al.. (2023). Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context. SHILAP Revista de lepidopterología. 4 indexed citations

12.

Lingas, Guillaume, Cédric Laouenan, Sarah Tubiana, et al.. (2023). High sera levels of SARS‐CoV‐2 N antigen are associated with death in hospitalized COVID‐19 patients. Journal of Medical Virology. 95(11). e29247–e29247. 3 indexed citations

13.

Tarhini, Hassan, Richard Dorent, Christine Randoux, et al.. (2023). Investigating infectious outcomes in adult patients undergoing solid organ transplantation: A retrospective single-center experience, Paris, France. PLoS ONE. 18(10). e0291860–e0291860. 3 indexed citations

14.

Protière, Christel, Luis Sagaon‐Teyssier, Gabriel Girard, et al.. (2023). Perception of PrEP‐related stigma in PrEP users: Results from the ANRS‐PREVENIR cohort. HIV Medicine. 24(8). 938–945. 3 indexed citations

15.

Bouscarat, F., Sonia Burrel, Nadhira Fidouh, et al.. (2022). Novel mutations in antiviral multiresistant HSV‐2 genital lesion: A case report. Journal of Medical Virology. 94(12). 6122–6126. 4 indexed citations

16.

Liégeon, Geoffroy & Jade Ghosn. (2022). Long‐acting injectable cabotegravir forPrEP: A game‐changer inHIVprevention?. HIV Medicine. 24(6). 653–663. 29 indexed citations

17.

Picard, B, et al.. (2021). Ambulatory anal self-sampling in MSM living with HIV, an acceptable and reliable screening method. PLoS ONE. 16(2). e0246338–e0246338. 6 indexed citations

18.

Perreau, Matthieu, Madeleine Suffiotti, Pedro Marques‐Vidal, et al.. (2021). The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. Nature Communications. 12(1). 4888–4888. 68 indexed citations

19.

Gantner, Pierre, Laurence Morand‐Joubert, Pierre Frange, et al.. (2019). “Real life” use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. PLoS ONE. 14(4). e0216010–e0216010. 2 indexed citations

20.

Chaix, Marie‐Laure, Faroudy Boufassa, Marianne Leruez‐Ville, et al.. (2017). Detectable HIV-RNA in semen of HIV controllers. PLoS ONE. 12(8). e0183376–e0183376. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact